UBC Highlights Research Supporting Melius' Clinical Development Program

UBC Okanagan recently published an article highlighting the research behind Melius MicroBiomics' lead engineered microbial therapeutic program for Inflammatory Bowel Disease (IBD).

A member of the Melius MicroBiomics research team conducting laboratory work at the Melius Laboratory in Kelowna, Canada.

The article describes a proof-of-concept study published in Gastroenterology by researchers in the laboratory of Melius Co-Founder & Chief Non-Executive Science Advisor, Dr. Deanna Gibson, at UBC Okanagan. The research demonstrated how beneficial bacteria can be engineered to thrive in an inflamed gut by using a byproduct of inflammation as a energy source.

These findings represent an important milestone in the scientific development of Melius' lead product candidate, MMB-003, which is currently being advanced toward first-in-human clinical evaluation in Australia.

Read the full UBC Okanagan article here

Read the scientific publication here

About Us

Melius MicroBiomics is a biotechnology company developing next-generation engineered live microbial products designed to improve human and animal health. Built on patented genetic engineering platforms and deep expertise in microbial ecosystems, Melius enhances the therapeutic potential of beneficial bacteria by enabling them to thrive under inflammatory conditions characteristic of many chronic diseases.

For more information, please visit https://www.mmblivebio.com and follow us on LinkedIn

Melius Media Contact:

Leah D'Aloisio

Medical Science Writer

Melius MicroBiomics, ldaloisio@mmblivebio.com